PIKfyve-specific inhibitors restrict replication of multiple coronaviruses in vitro but not in a murine model of COVID-19 | Communications Biology - Nature.com

Compound-testing in a murine model for COVID-19 show that the prophylactic or therapeutic application of Apilimod and other PIKfyve inhibitors, the former being considered for human Phase II trials, worsens disease outcome with higher lung viral load and mort…

Virus and cells All work with SARS-CoV-2 was performed in an A/BSL3 laboratory and approved by our Institutional Biosafety Committee (IBC# IBC-00005484) and Institutional Animal Care and Use Committ… [+10996 chars]

full article...